BioXcel Therapeutics, Inc. (NASDAQ: BTAI), a biopharmaceutical company leveraging artificial intelligence in drug development, has secured a significant milestone in its intellectual property (IP) portfolio. The European Patent Office granted Patent No. 3,562,486 on March 13, 2024, covering a range of sublingual dosage forms, such as films, wafers, and tablets, for BioXcel’s dexmedetomidine treatment for